Use this link to cite:

https://hdl.handle.net/2183/47181

Mumps: A year of enhanced surveillance in Catalonia, Spain

Thumbnail Image

Files

(9999-12-31)Dominguez_Angela_2009_Mumps.pdf (133.63 KB)

Identifiers

URI: https://hdl.handle.net/2183/47181
DOI: 10.1016/j.vaccine.2009.03.022

Publication date

2009-03-31

Authors

Domínguez, Àngeles
Torner, Nuria
Carmona, Glòria
Costa, Josep
Caylà, Joan A.
Sala, M. Rosa
Barrabeig, Irene
Camps, Neus
Minguell, Sofía

Advisors

Other responsabilities

Journal Title

Bibliographic citation

Dominguez, A., Oviedo, M., Torner, N., Carmona, G., Costa, J., Caylà, J., Sala, M. R., Barrabeig, I., Camps, N., & Minguell, S. (2009). Mumps: A year of enhanced surveillance in Catalonia, Spain. Vaccine, 27(25-26), 3492-3495. https://doi.org/10.1016/j.vaccine.2009.03.022

Type of academic work

Academic degree

Abstract

[Abstract]: Mumps is a vaccine-preventable disease candidate for elimination. Positive predictive value (PPV) of clinical case definition was assessed. During 2007, 410 suspected cases were reported in Catalonia: 348 fulfilled clinical case definition and 159 were laboratory confirmed. Incidence rate was 4.8 per 100,000 for cases that fulfilled the clinical definition, and 2.2 for laboratory confirmed cases. Global PPV was 44.5%; 38.5% in <15 years and 50% in ≥15 years (p = 0.04). Most laboratory confirmed cases (72.3%) received at least one MMR dose. With sustained high MMR coverage, laboratory confirmation is necessary to control the disease and assess vaccine failure.

Description

Keywords

Mumps Enhanced surveillance Laboratory confirmation

Editor version

https://doi.org/10.1016/j.vaccine.2009.03.022

Rights

© 2009 Elsevier Ltd. All rights reserved

Collections

Investigación (FIC)